Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research report report published on Wednesday, Benzinga reports. They currently have a $9.00 price objective on the stock.

Alpha Tau Medical Price Performance

DRTS stock opened at $2.71 on Wednesday. The firm has a market cap of $188.81 million, a price-to-earnings ratio of -6.61 and a beta of 0.75. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.07. Alpha Tau Medical has a 12-month low of $2.15 and a 12-month high of $4.80. The company’s fifty day simple moving average is $2.72 and its 200 day simple moving average is $2.94.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. On average, analysts expect that Alpha Tau Medical will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Alpha Tau Medical

Institutional investors have recently made changes to their positions in the stock. USAdvisors Wealth Management LLC acquired a new position in shares of Alpha Tau Medical during the first quarter valued at about $30,000. Telemus Capital LLC acquired a new position in shares of Alpha Tau Medical during the fourth quarter valued at about $89,000. Satovsky Asset Management LLC acquired a new position in shares of Alpha Tau Medical during the fourth quarter valued at about $176,000. Private Advisor Group LLC acquired a new position in shares of Alpha Tau Medical during the fourth quarter valued at about $176,000. Finally, Levin Capital Strategies L.P. raised its holdings in shares of Alpha Tau Medical by 288.4% during the fourth quarter. Levin Capital Strategies L.P. now owns 330,123 shares of the company’s stock valued at $994,000 after purchasing an additional 245,123 shares during the period. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.